ADIPOQ and breast cancer: Based on an analysis of a large cohort of breast cancer patients, circulating adipokines (leptin, adiponectin and resistin) measured shortly after diagnosis and/or five years later were not found to be independent prognostic factors of long-term all-cause mortality, BCM or risk of recurrence after accounting for BMI, tumor characteristics, treatment and lifestyle.